News and Events

Date Subject
2019-09-18Curry Health Network Adopts ClickClean™ Advanced Laparoscopic Technology

Curry Health Network Adopts ClickClean™ Advanced Laparoscopic Technology

Curry Health Network Adopts ClickClean™ Advanced Laparoscopic Technology

Adoption furthers Curry Health Network’s commitment to providing patients premium surgical experiences

September 17, 2019 Gold Beach, OR – Curry Health Network, an integrated health care delivery system based here, today announced that its flagship hospital, Curry General Hospital, has recently adopted the ClickClean™ advanced laparoscopic device, manufactured by Medeon Biodesign (Taipei, Taiwan). Adopting meaningful technologies that drive positive change and benefit patients directly is an integral part of Curry Health Network’s mission to promote healthy communities with efficient, quality health care, making ClickClean an ideal solution for its surgeons performing laparoscopy.

ClickClean provides physicians performing laparoscopic surgery a sustained clear view of the surgical area through a simple “click and clean” in-situ cleaning mechanism. This can significantly reduce the length of laparoscopic procedures, as well as reduce risks associated with obstructed vision, such as scope damage and procedure-associated infections.

“Having the ClickClean device with me during surgery has proven invaluable,” commented Curry Health Network’s (CHN) general surgeon, Jessica Carlson, M.D. “If you can’t see very well during a gall bladder surgery, for example, it makes the entire procedure about twice as difficult. To maintain a clear view, I used to have to remove and clean my surgical camera every 5 minutes. Now I can clean my camera lens with the click of a button, helping me stay focused on the surgery itself with less attention paid to camera maintenance. It’s an incredibly simple and useful technology that benefits me, and subsequently, my patients immensely.”

“Ensuring our patients have access to the latest surgical advancements is a key part of our mission,” added Virginia (Ginny) Williams, Chief Executive Officer of Curry Health Network. “We are always searching for technologies that help our physicians deliver better outcomes and improve safety wherever possible.

Medeon’s philosophy – to deliver high-impact, high-value devices – aligns soundly with CHN’s mission, as we strive to put these types of technologies to work for our patients.”

About Curry Health Network

Curry Health Network is committed to providing high quality health care with service excellence, close to home. Curry Health Network is comprised of a hospital and several medical clinics located on the southern Oregon coast. Curry Health Network is an Oregon special health district, a form of local government and municipal corporation that has been granted 501(c)(3) status by the Internal Revenue Service.

For more information, visit www.CurryHealthNetwork.com.

About ClickClean

ClickClean is a single use, disposable device that instantly restores a surgeon’s clarity of view in-situ with no scope removal required. The design sheaths the laparoscope and covers the lens with a clear film. As the visual field is soiled by blood and debris, a simple click will advance clean film over the distal end, giving the surgeon a clear unobstructed view. ClickClean is 510(k) cleared by the United States Food and Drug Administration (US-FDA) and has successfully demonstrated its simplicity, ease-of-use and clinical value in numerous clinical cases throughout the US.

For more information, visit www.clickclean-medeon.com.

About Medeon Biodesign

Medeon Biodesign is a publicly traded company located in Taipei, Taiwan, and currently listed on Taipei Exchange (TPEx: 6499). The company focuses on the development of high-impact, high-value medical devices that help treat diseases with sizable patient populations, such as cardiovascular, peripheral vascular, orthopedic, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology,urology, and plastic surgery.

For more information, please visit www.medeonbio.com.

Media Contacts:

Cheryl McDermott

Curry Health Network

541-247-3192

cheryl.mcdermott@curryhealth.org

 

Genevieve Britton

Pascale Communications, LLC.

512.774.0735

genevieve@pascalecommunications.com

2019-07-08Medeon Led and Completed Investments in Panther Orthopedics and Prodeon

Medeon Led and Completed Investments in Panther Orthopedics and Prodeon

Medeon Led and Completed Investments in Panther Orthopedics and Prodeon

TAIPEI, July 8th, 2019 – Medeon Biodesign, Inc. (TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce that it recently led and closed two investments, in Panther Orthopedics and Prodeon. Panther Orthopedics is a Silicon Valley startup company pioneering innovative dynamic fixation solutions for orthopedic extremity applications. Prodeon is a Taiwan-based company offering a simple, office-based treatment option for patients who are seeking immediate relief from lower urinary tract symptoms (LUTS) caused by Benign Prostatic Hyperplasia (BPH).

Panther Orthopedics’ U.S. Food and Drug Administration 510(k) cleared PUMA System (TM) is a revolutionary advancement in the treatment of orthopedic injuries that provides the benefits of screws and flexible fixation devices but without their short comings. The spring-like design of the PUMA Body provides initial and continuous compression without the need to overtighten. The PUMA System (TM) has been commercially available since November 2018, and continues to accumulate outstanding clinical experiences.

Prodeon’s investigational device, the XFLO (TM) Expander System, addresses the significant unmet clinical need for treating patients living with BPH and LUTS. Demographics show that about 50% of men aged 50 years and above experience LUTS attributable to BPH, and in men over 80 years old, the incidence rises to over 80%, representing over 71 million actively managed patients worldwide. Drugs and conventional surgical treatments are associated with side effects and complications, including compromised sexual function, bleeding, infections, and long recovery times. Recently, less invasive BPH treatment options with significant clinical advantages are actively and significantly expanding the underpenetrated BPH market. XFLO (TM) is a novel, minimally-invasive, and office-based treatment that provides a simple and less invasive option over conventional surgery or drugs for resolving BPH symptoms. The XFLO (TM) Expander System successfully completed its first clinical use in Australia and the Republic of Georgia.

“Medeon has built an innovation platform that partners with physicians and entrepreneurs to solve unmet medical needs, by bringing innovative ideas from concept to commercialization. With both the resources to fund projects and the capabilities to execute them, this platform combines the strengths of a traditional medtech venture capital firm and those of a medtech development firm. The two recent investments, in Panther Orthopedics and Prodeon, are perfect examples of executing this unique business model with a combination of funding, development expertise, manufacturing capabilities, and industry relations to accelerate medtech development,” said Dr. Yue-Teh Jang, Chairman and CEO of Medeon.

About Medeon Biodesign

Medeon Biodesign (TPEx: 6499) is a publicly traded company located in Taipei, Taiwan, and currently listed on Taipei Exchange. The company focuses on the development of medical devices for minimally invasive surgeries to treat diseases of sizable patient population, such as cardiovascular, peripheral vascular, orthopedic, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery. For more information, please visit www.medeonbio.com/en.

Contacts

Medeon Biodesign:

Dr. Jenny Chen

TEL: +886.2.2881.6686

Email: IR@medeonbio.com

2019-06-27Panther Orthopedics Announces Successful Closing of Financing and Expanded Clinical Use of the PUMA System (TM)

Panther Orthopedics Announces Successful Closing of Financing and Expanded Clinical Use of the PUMA System (TM)

Panther Orthopedics Announces Successful Closing of Financing and Expanded Clinical Use of the PUMA System (TM)

Sunnyvale, California, June 27, 2019 – Panther Orthopedics, Inc., a pioneer developing innovative dynamic fixation solutions for orthopedic extremity applications, is pleased to announce the successful closing of its Series B financing led by Medeon Biodesign and expanded clinical use of its PUMA System (TM).

 

The PUMA System (TM) obtained U.S. Food and Drug Administration 510(k) approval in early 2018, and was commercially launched in November 2018 in the United States. Through the clinical cases, it has demonstrated tremendous clinical benefits over conventional screws and flexible fixation devices without their shortcomings. The novel spring-like design of the PUMA body provides initial and continuous compression without the need to overtighten.

“Panther Orthopedics offers a novel “dynamic fixation” solution to the significant market by providing continuous compression without creep during the healing phase while allowing for physiological micro-motion. With the outstanding initial clinical experiences and additional financing backing, Panther Orthopedics can now continue to expand the clinical and commercial operations. We are exciting to observe more and more patients benefitting from this innovative flexible fixation device” said Kathy Stecco, M.D., CEO and co-founder of Panther Orthopedics.

“The novel PUMA System (TM) brings a technology to address current shortcomings in syndesmotic fixation. Nitinol use in foot and ankle surgery has exploded in recent years, demonstrating that its use is becoming more understood by surgeons. Thus, this fixation technique provides what we need – ease of use, maintenance of reduction, and dynamic fixation without creep. This fixation mimics more of the natural biomechanics of the ankle. We believe this will lead to better ankle function and clinical outcomes” Said J. Kent Ellington, M.D., Orthopedic Surgeon, OrthoCarolina Foot and Ankle Institute.

“Around one million fracture fixation procedures are performed in the United States every year, and the number of procedures continues to grow, primarily due to an aging, obese population and lifestyle influences. As the lead Series B investor of Panther Orthopedics, Medeon will continue to provide resources – not only funding, but also development expertise, manufacturing capabilities, and industry connections to accelerate their development to serve this significant and growing market” said Dr. Yue-Teh Jang, Chairman and CEO of Medeon Biodesign.

About Panther Orthopedics

Panther Orthopedics, Inc., based in Sunnyvale, California, USA is developing next level dynamic fixation solutions for orthopedic trauma and sports medicine applications. Its first product, the PUMA System (TM), is currently indicated for Syndesmosis Fixation, Hallux Valgus Reconstruction, and Tarsometatarsal Fixation.

About Medeon Biodesign

Medeon Biodesign (TPEx: 6499) is a publicly traded company located in Taipei, Taiwan, and currently listed on Taipei Exchange. The company focuses on the development of medical devices for minimally invasive surgeries to treat diseases of sizable patient population, such as cardiovascular, peripheral vascular, orthopedic, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery. For more information, please visit www.medeonbio.com/en.

Contacts

Panther Orthopedics:

Kathy Stecco, M.D.

TEL: +1-669-247-6985

Email: info@pantherortho.com

Medeon Biodesign:

Jenny Chen, Ph.D.

TEL: +886-2-2881-6686

Email: IR@medeonbio.com